HIV drug resistance in newly diagnosed adults in a rural prefecture of eastern China

Abstract

Little is known about HIV drug resistance (HIVDR) in newly diagnosed HIV-infected adults in eastern China where the HIV epidemic is spreading predominantly through sexual contact. During 2008-2011, newly HIV-diagnosed adults in Taizhou prefecture, Zhejiang province in eastern China were examined for HIVDR by amplifying and sequencing the HIV-1 pol gene. Of 447 genotyped participants, 53·7% were infected with CRF01_AE, 20·1% with CRF07_BC, 12·5% with subtype B, and 11·6% with CRF08_BC. Most of the participants had one or more minor genetic mutations in the pol gene that are associated with HIVDR. Twelve (2·7%) participants met the standard guidelines of having low to high HIVDR, suggesting that the prevalence of HIVDR in newly HIV-diagnosed adults was low in the study area and current antiretroviral therapy (ART) regimens are likely to remain effective. However, given high frequency of minor HIVDR in HIV patients and the scaling up of ART programmes in China, larger HIVDR surveillance programmes are needed.

Genetic diversity of HIV-1 and transmitted drug resistance among newly diagnosed individuals with HIV infection in Hangzhou, China

“…We found that the overall prevalence of primary DR was 4.0%. This prevalence was comparable to that of previous studies in China, which showed 3.8% TDR in China during 2004 and 2005 [Liao et al, 2010], 3.2% in Guangxi in 2013 , 2.7% in Taizhou prefecture during 2008-2011 [Hua et al, 2015], 4.9% among MSM in 19 provinces/cities in 2010 [Yang et al, 2013]. The prevalence of DR in our study which categorized as low level was similar to Southern Vietnam [Tanuma et al, 2014] and Malaysia [Ong et al, 2014] on the whole, but lower than those in North America and Western Europe where TDR rates were reported to be 13.6% and 6.8% during 2004 to 2006 [Rahim et al, 2009], respectively.…”

“…This prevalence was comparable to that of previous studies in China, which showed 3.8% TDR in China during 2004 and 2005 [Liao et al, 2010], 3.2% in Guangxi in 2013 , 2.7% in Taizhou prefecture during 2008-2011 [Hua et al, 2015], 4.9% among MSM in 19 provinces/cities in 2010 [Yang et al, 2013]. The surveillance of TDR in China has particularly important public health significance owing to the limited resources of antiretroviral drugs.…”

“…Though the prevalence of HIV TDR in China was low (3.8%) during 2004 and 2005 [Liao et al, 2010], it may have increased in recent years due to the long-term and extensive implementation of HAART. In general, published data regarding TDR in China are sporadic and limited Zhong et al, 2007;Liao et al, 2010;Zhang et al, 2012;Zhao et al, 2011;Yang et al, 2013;Chen et al, 2014;Li et al, 2014;Hua et al, 2015], continuous and extensive surveillance on newly diagnosed HIV-positive individuals is needed to ensure that the antiretroviral therapy (ART) is adjusted to the evolution of drug resistance (DR).…”

Survey of Pretreatment HIV Drug Resistance and Genetic Transmission Network Analysis Among HIV Patients in a High Drug-Use Area of Southwest China

“…The overall prevalence of PDR among the studied samples was 6.9%, and PDR in three years between 2016-2018 achieved a moderate level (5%-15%) according to the WHO categorization method [ 33 ]. The HIVDR rate was higher than that of previous studies in Liangshan [ 44 ] and other regions in China [ 38 , 45 ]. However, the resistance rate was lower than those in Kenya and Mexico, where PDR rates were reported to be 21.9% and 15.5% [ 46 , 47 ], respectively.…”

The infection staging and profile of genotypic distribution and drug resistance mutation among the human immunodeficiency virus-1 infected blood donors from five Chinese blood centers, 2012–2014

“…Henan province) are subtype B[8] and the major subtype at southeastern and eastern coastal area is subtype 01_AE. [21, 34, 35] The variations in subtype distribution might be due to different transmission patterns and status of co-evolution between virus and population, which couldn’t be confirmed in this study. The main subtypes found at Urumqi and Liuzhou blood centers: CRF07_BC and CRF01_AE, were the same as in our previous REDS-II findings[10], which were also consistent with the subtype distributions among high-risks groups at these two regions[36, 37].…”